₹1,100.00
ABICET-M
ABICET-M combines two formulations of Levocetirizine and Montelukast Tablets, which are intended to treat sneezing and runny nose caused by allergies, as well as hay fever and allergic skin problems. Levocetirizine is an anti-allergic medication that prevents the release of a chemical messenger (histamine) that causes a runny nose, watery eyes, and sneezing. Montelukast, on the other hand, belongs to a medication class known as a leukotriene antagonist, which aids in the blockage of another chemical messenger, decreases inflammation (swelling) in the airways and nose, and relieves allergy symptoms.
Precautions For Levocetirizine And Montelukast Tablets
Levocetirizine and Montelukast Tablets should be taken after having a meal with water. As a side effect, dry mouth may occur. Frequent mouth rinses, improved dental hygiene, increased water consumption, and sugarless sweets may be beneficial.
Side Effects Of Levocetirizine And Montelukast Tablets
If a person’s allergic skin problems worsen after using Levocetirizine and Montelukast Tablets, for example, if they have Urticaria (another term for hives), they will have itchy, red, and raised patches on their skin. On the other hand, if they develop Dermatitis (skin inflammation), it may manifest as red and itchy skin. In such circumstances, the patient should seek medical attention.
Abigail Healthcare always emphasizes bringing the latest and best solutions for skin issues. It makes the company the best derma organisation in the nation. Our company has an ISO certification and works as per the norms set by WHO and GMP in order to match the international standard of the products. We are considered as a special Levocetirizine and Montelukast Tablets manufacturer and supplier in India as well as our company also offering PCD Derma Franchise for Levocetirizine and Montelukast Tablets along with numerous benefits.
Brand Name | ABICET-M |
---|---|
Composition | Levocetirizine 5mg + Montelukast 10mg |
Pack Type | ALU-ALU |
Pack Size |
There are no enquiries yet.